SOPs for Nanoparticle Formulation

This SOP outlines the procedure for incorporating surfactants in nanoparticle formulations. Surfactants are essential for stabilizing nanoparticles by reducing surface tension, preventing aggregation, and ensuring uniform particle size distribution.
Click to read the full article.

The purpose of this SOP is to outline the procedure for the preparation of solid lipid nanoparticles (SLNs). SLNs are colloidal carriers made from solid lipids, offering controlled drug release and enhanced bioavailability for various pharmaceutical and cosmetic applications.
Click to read the full article.

This SOP outlines the steps for preparing nanoparticles designed for targeted drug delivery, which can enhance therapeutic efficacy and minimize off-target effects of drugs.
Click to read the full article.

The purpose of this SOP is to outline the procedure for incorporating bioadhesive polymers in nanoparticle formulations. Bioadhesive polymers enhance the mucoadhesion of nanoparticles, allowing for prolonged retention time at the site of administration (e.g., gastrointestinal tract, nasal cavity), improving drug bioavailability and therapeutic effectiveness.
Click to read the full article.

This SOP outlines the procedure for preparing dendrimers, which are branched polymers used for drug delivery applications. Dendrimers provide controlled drug release and targeted delivery properties.
Click to read the full article.

This SOP outlines the procedure for incorporating stabilizers into nanoparticle-based formulations to enhance their stability, prevent aggregation, and improve shelf life.
Click to read the full article.

This SOP outlines the procedure for preparing sterile nanoparticles for intravenous (IV) administration, ensuring the formulation is suitable for direct injection into the bloodstream for therapeutic use.
Click to read the full article.

The purpose of this SOP is to outline the procedure for incorporating antioxidants in nanoparticle formulations. Antioxidants are used to prevent oxidative degradation of both the active pharmaceutical ingredients (API) and the carrier material, ensuring improved stability, bioavailability, and efficacy.
Click to read the full article.

This SOP outlines the procedure for the preparation of magnetic nanoparticles used in biomedical applications, such as targeted drug delivery, magnetic resonance imaging (MRI), and hyperthermia treatment.
Click to read the full article.

The purpose of this SOP is to outline the procedure for developing nanoparticle-based formulations for oral drug delivery. Nanoparticles offer improved bioavailability, protection of the active pharmaceutical ingredient (API) from the harsh gastrointestinal (GI) environment, and targeted drug release.
Click to read the full article.